Evidence map›Paper›PMID 38177202›Full record

ArticleScientific reports2024

Optimization, characterization, and cytotoxicity studies of novel anti-tubercular agent-loaded liposomal vesicles.

Manar M Obiedallah, Maxim A Mironov, Danila V Belyaev, Antoaneta Ene, Diana V Vakhrusheva, Svetlana Yu Krasnoborova, Sergey Y Bershitsky, Daniil V Shchepkin, Artem S Minin, Rashida I Ishmetova and 4 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 3 countries.

Manar M ObiedallahInstitute of Chemical Technology, Ural Federal University, Yekaterinburg, Russia. m.mh.obid@gmail.com.
Maxim A MironovInstitute of Chemical Technology, Ural Federal University, Yekaterinburg, Russia. m.a.mironov@urfu.ru.
Danila V BelyaevI. Postovsky Institute of Organic Synthesis, Ural Branch of the Russian Academy of Sciences, S. Kovalevskaya Str. 22, Yekaterinburg, 620108, Russia.
Antoaneta EneINPOLDE Research Center, Department of Chemistry, Physics and Environment, Faculty of Sciences and Environment, Dunarea de Jos University of Galati, 47 Domneasca Street, 800008, Galati, Romania. Antoaneta.Ene@ugal.ro.
Diana V VakhrushevaNational Medical Research Center of Phthisiopulmonology and Infectious Diseases, 22 Parts'ezda St., 50, Yekaterinburg, 620039, Russia.
Svetlana Yu KrasnoborovaNational Medical Research Center of Phthisiopulmonology and Infectious Diseases, 22 Parts'ezda St., 50, Yekaterinburg, 620039, Russia.
Sergey Y BershitskyInstitute of Immunology and Physiology, Ural Branch of Russian Academy of Sciences, Yekaterinburg, 620049, Russia.
Daniil V ShchepkinInstitute of Natural Sciences and Mathematics, Ural Federal University, Yekaterinburg, Russia.
Artem S MininM.N. Mikheev Institute of Metal Physics of the Ural Branch of the Russian Academy of Sciences, S.Kovalevskaya St. 18, Yekaterinburg, 620108, Russia.
Rashida I IshmetovaI. Postovsky Institute of Organic Synthesis, Ural Branch of the Russian Academy of Sciences, S. Kovalevskaya Str. 22, Yekaterinburg, 620108, Russia.
Nina K IgnatenkoI. Postovsky Institute of Organic Synthesis, Ural Branch of the Russian Academy of Sciences, S. Kovalevskaya Str. 22, Yekaterinburg, 620108, Russia.
Svetlana G TolshchinaI. Postovsky Institute of Organic Synthesis, Ural Branch of the Russian Academy of Sciences, S. Kovalevskaya Str. 22, Yekaterinburg, 620108, Russia.
Olga V FedorovaI. Postovsky Institute of Organic Synthesis, Ural Branch of the Russian Academy of Sciences, S. Kovalevskaya Str. 22, Yekaterinburg, 620108, Russia.
Gennady L RusinovInstitute of Chemical Technology, Ural Federal University, Yekaterinburg, Russia.
Institute of Organic Synthesis · RUUral Federal University · RUUral research Institute of Phthisiopulmonology · RUAssiut University · EG"Dunarea de Jos" University of Galati · ROInstitute of Immunology and Physiology · RUM.N. Mikheev Institute of Metal Physics · RUUral Branch of the Russian Academy of Sciences · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of tuberculosis is still a challenging process due to the widespread of pathogen strains resistant to antibacterial drugs, as well as the undesirable effects of anti-tuberculosis therapy. Hence, the development of safe and effective new anti-antitubercular agents, in addition to suitable nanocarrier systems, has become of utmost importance and necessity. Our research aims to develop liposomal vesicles that contain newly synthesized compounds with antimycobacterial action. The compound being studied is a derivative of imidazo-tetrazine named 3-(3,5-dimethylpyrazole-1-yl)-6-(isopropylthio) imidazo [1,2-b] [1,2,4,5] tetrazine compound. Several factors that affect liposomal characteristics were studied. The maximum encapsulation efficiency was 53.62 ± 0.09. The selected liposomal formulation T8* possessed a mean particle size of about 205.3 ± 3.94 nm with PDI 0.282, and zeta potential was + 36.37 ± 0.49 mv. The results of the in vitro release study indicated that the solubility of compound I was increased by its incorporation in liposomes. The free compound and liposomal preparation showed antimycobacterial activity against Mycobacterium tuberculosis H

Indexed as

Mycobacterium tuberculosisTuberculosisAntitubercular AgentsHumansLiposomesMicrobial Sensitivity TestsAntitubercular AgentsLiposomes

Identifiers

PMID38177202
PMCPMC10766644
OpenAlexW4390581000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.